Jaguar Health Croissance future
Future contrôle des critères 0/6
Le chiffre d'affaires de Jaguar Health devrait diminuer de 40.6% par an, tandis que ses bénéfices annuels devraient croître de 124.7% par an. Le BPA devrait croître de , augmenter de 148.2% par an.
Informations clés
124.7%
Taux de croissance des bénéfices
148.24%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 14.7% |
| Taux de croissance des recettes | -40.6% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 12 Feb 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • Jun 06
JAGX: Nasdaq Listing Risk Will Set Up Future Upside Repricing
Narrative Update on Jaguar Health The analyst price target for Jaguar Health has been reduced by $262.50. Analysts point to sharply lower revenue growth expectations and a modestly higher projected profit margin as key reasons for the reset.Mise à jour du récit • May 17
JAGX: Nasdaq Delisting Risk Will Set Up Future Upside Repricing
Analysts have reset Jaguar Health's fair value estimate from $7.50 to $262.50, reflecting a revised view on the discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Nasdaq staff issued a delisting notice on May 1, 2026, citing Jaguar Health's publicly held shares of common stock of approximately 401,226 after the 1 for 35 reverse stock split, which is below the 500,000 minimum required for continued listing under Nasdaq Listing Rule 5550(a)(4) (Nasdaq notice).Mise à jour du récit • Apr 25
JAGX: Nasdaq Listing Risk Will Set Up Future Upside Repricing
Analysts have adjusted their price target for Jaguar Health to $7.50, reflecting updated views on the company’s profit margin profile and long term P/E expectations, while keeping fair value and growth assumptions broadly in line with prior estimates. What's in the News Jaguar Health filed its 10-K on April 7, 2026, with auditor RBSM LLP issuing an unqualified opinion.Mise à jour du récit • Apr 10
JAGX: Nasdaq Listing Risk Will Drive Future Upside Repricing Potential
Analysts have adjusted their price target for Jaguar Health to reflect updated assumptions for slower revenue growth, largely unchanged profit margins, and a substantially higher forward P/E multiple. What's in the News Jaguar Health reported that it will be unable to file its next 10-K by the SEC deadline, indicating a delay in required financial reporting (SEC filing announcement).Mise à jour du récit • Mar 27
JAGX: Nasdaq Listing Risk Will Trigger Future Upside Repricing Potential
Analysts now place Jaguar Health's price target at $7.50, consistent with the prior $7.50 view. They cite broadly unchanged fair value, discount rate and revenue growth assumptions, alongside a slightly lower profit margin outlook and a modestly higher future P/E expectation.Mise à jour du récit • Mar 12
JAGX: Nasdaq Listing Risk Will Set Up Potential Upside Repricing
Analysts maintained their $7.50 price target for Jaguar Health, citing a higher discount rate and slightly lower assumed profit margins, partly offset by a higher future P/E assumption, as the key factors in their updated model. What's in the News On March 5, 2026, Nasdaq notified Jaguar Health that its common stock had closed below the minimum US$1.00 bid price for 30 consecutive business days, leaving the company out of compliance with Nasdaq Listing Rule 5550(a)(2) (Key Developments).Mise à jour du récit • Feb 25
JAGX: Short Term Funding Will Support Improved Profitability Expectations
Analysts have reset their price target for Jaguar Health from $28 to $7.50. They now apply a lower discount rate, more moderate revenue growth expectations, slightly tighter profit margin assumptions, and a higher future P/E multiple in their updated model.
Mise à jour du récit • Feb 09
JAGX: Recent Debt Financing Will Support Upside Potential
Analysts have slightly adjusted their fair value estimate for Jaguar Health to US$35.00. This reflects small tweaks to discount rate, revenue growth and future P/E assumptions rather than a major shift in their overall thesis.Mise à jour du récit • Jan 25
JAGX: Near Term Debt Funding And Shareholder Votes Will Support Upside Potential
Analysts have adjusted their price target for Jaguar Health to US$35.00, reflecting updated views on fair value, discount rate, growth assumptions and future P/E that they consider better aligned with the stock's current risk and return profile. What's in the News Jaguar Health entered into a securities purchase agreement on January 6, 2026, for unsecured promissory notes with an aggregate principal amount of US$350,000, carrying 6% annual interest and maturing one month after issuance (Key Developments).Mise à jour du récit • Jan 11
JAGX: Upcoming Debt Funding And Shareholder Votes Will Support Upside Potential
Analysts have slightly adjusted their fair value target for Jaguar Health to US$35.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping the headline price target level unchanged. What's in the News On November 24, 2025, Jaguar Health, Inc.Mise à jour du récit • Dec 26
JAGX: Future Private Placements Will Support Balance Sheet And Upside Potential
Analysts have raised their price target on Jaguar Health to 35.00 dollars, reflecting slightly higher long term revenue growth assumptions and a modestly higher discount rate. Together these factors keep fair value effectively unchanged while acknowledging incremental upside potential.Mise à jour du récit • Dec 12
JAGX: Future Capital Raises Will Strengthen Balance Sheet And Support Upside Potential
Analysts have modestly reduced their price target on Jaguar Health to reflect a lower fair value estimate of 35 dollars from 40 dollars, even as they factor in stronger revenue growth and a higher future price to earnings multiple, partially offset by slightly softer profit margin assumptions and a lower discount rate. What's in the News Jaguar Health closed a private placement transaction on November 24, 2025, further advancing its ongoing capital raising efforts (Key Developments).Article d’analyse • Aug 29
Slammed 27% Jaguar Health, Inc. (NASDAQ:JAGX) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Jaguar Health, Inc. ( NASDAQ:JAGX ) shares are down a considerable 27% in the...Article d’analyse • Jul 02
Investors Give Jaguar Health, Inc. (NASDAQ:JAGX) Shares A 43% Hiding
The Jaguar Health, Inc. ( NASDAQ:JAGX ) share price has fared very poorly over the last month, falling by a substantial...
Nouveau récit • Apr 18
FDA And EMA Fast-Track Approvals Will Advance Orphan Treatments
New collaborations and regulatory approvals could quicken market entry, increase revenue, and improve earnings through enhanced access to global markets for orphan disease treatments.Article d’analyse • Feb 05
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 30%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shares have had a horrible month, losing 30% after a relatively good period...Article d’analyse • Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shareholders won't be pleased to see that the share price has had a very rough...Article d’analyse • Nov 09
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 27%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shares have had a horrible month, losing 27% after a relatively good period...Article d’analyse • Jul 24
Jaguar Health, Inc. (NASDAQ:JAGX) Stock's 55% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, Jaguar Health, Inc. ( NASDAQ:JAGX ) shares are down a considerable 55% in the...Article d’analyse • May 24
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%
Jaguar Health, Inc. ( NASDAQ:JAGX ) shares have retraced a considerable 49% in the last month, reversing a fair amount...Article d’analyse • Mar 29
Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth
Jaguar Health, Inc. ( NASDAQ:JAGX ) shareholders are no doubt pleased to see that the share price has bounced 55% in...Article d’analyse • Jan 22
Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%
Unfortunately for some shareholders, the Jaguar Health, Inc. ( NASDAQ:JAGX ) share price has dived 39% in the last...Article d’analyse • Jun 10
Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump
To the annoyance of some shareholders, Jaguar Health, Inc. ( NASDAQ:JAGX ) shares are down a considerable 32% in the...Article d’analyse • Jan 23
Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2027 | 14 | -6 | -4 | -3 | 1 |
| 12/31/2026 | 20 | -2 | 2 | 2 | 1 |
| 3/31/2026 | 30 | -50 | -8 | -8 | N/A |
| 12/31/2025 | 12 | -54 | -24 | -24 | N/A |
| 9/30/2025 | 12 | -40 | -26 | -26 | N/A |
| 6/30/2025 | 12 | -41 | -28 | -28 | N/A |
| 3/31/2025 | 12 | -40 | -30 | -30 | N/A |
| 12/31/2024 | 12 | -38 | -30 | -29 | N/A |
| 9/30/2024 | 10 | -38 | -29 | -29 | N/A |
| 6/30/2024 | 10 | -36 | -29 | -29 | N/A |
| 3/31/2024 | 10 | -38 | -30 | -30 | N/A |
| 12/31/2023 | 10 | -41 | -33 | -33 | N/A |
| 9/30/2023 | 11 | -40 | -33 | -32 | N/A |
| 6/30/2023 | 11 | -44 | -34 | -34 | N/A |
| 3/31/2023 | 11 | -42 | -37 | -35 | N/A |
| 12/31/2022 | 12 | -47 | -35 | -33 | N/A |
| 9/30/2022 | 11 | -54 | -37 | -36 | N/A |
| 6/30/2022 | 8 | -54 | -38 | -37 | N/A |
| 3/31/2022 | 6 | -59 | -36 | -36 | N/A |
| 12/31/2021 | 4 | -53 | -35 | -35 | N/A |
| 9/30/2021 | 5 | -50 | -30 | -30 | N/A |
| 6/30/2021 | 7 | -46 | -24 | -24 | N/A |
| 3/31/2021 | 10 | -42 | -18 | -18 | N/A |
| 12/31/2020 | 9 | -39 | -15 | -15 | N/A |
| 9/30/2020 | 8 | -35 | -14 | -14 | N/A |
| 6/30/2020 | 7 | -39 | -20 | -20 | N/A |
| 3/31/2020 | 5 | -45 | -21 | -21 | N/A |
| 12/31/2019 | 6 | -45 | N/A | -20 | N/A |
| 9/30/2019 | 6 | -48 | N/A | -22 | N/A |
| 6/30/2019 | 6 | -43 | N/A | -16 | N/A |
| 3/31/2019 | 5 | -34 | N/A | -17 | N/A |
| 12/31/2018 | 4 | -32 | N/A | -23 | N/A |
| 9/30/2018 | 4 | -41 | N/A | -23 | N/A |
| 6/30/2018 | 4 | -30 | N/A | -23 | N/A |
| 3/31/2018 | 4 | -24 | N/A | -19 | N/A |
| 12/31/2017 | 4 | -22 | N/A | -10 | N/A |
| 9/30/2017 | 3 | -5 | N/A | -7 | N/A |
| 6/30/2017 | 2 | -14 | N/A | -17 | N/A |
| 3/31/2017 | 1 | -17 | N/A | -15 | N/A |
| 12/31/2016 | 0 | -15 | N/A | -14 | N/A |
| 12/31/2015 | 0 | 5 | N/A | 1 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: JAGX devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: JAGX devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: JAGX devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Les revenus de JAGX devraient diminuer au cours des 3 prochaines années ( -40.6% par an).
Croissance élevée des revenus: Les revenus de JAGX devraient diminuer au cours des 3 prochaines années ( -40.6% par an).
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de JAGX devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/17 11:39 |
| Cours de l'action en fin de journée | 2026/06/17 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Jaguar Health, Inc. est couverte par 2 analystes. 1 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Robert LeBoyer | Aegis Capital Corporation |
| Christian Orquera | First Berlin Equity Research GmbH |